Breaking News

Sorrento Appoints Translational Medicine SVP

April 8, 2014

Walters brings 15 years of drug development and business experience

Ian B. Walters, M.D., has been appointed senior vice president of translational medicine and corporate development at Sorrento Therapeutics, Inc. Dr. Walters has more than 15 years of drug development and business experience in both small biopharma and big pharma companies. He joins the company from Bristol Myers Squibb, where he led oncology drug development programs, large international matrix teams, and strategic transactions.  
 
Dr. Walters spent seven years with BMS, most recently working with the Strategic Transactions Group to evaluate and execute licensing agreements, mergers and acquisitions, clinical collaborations, as well as BMS' immune-oncology strategy. Previously he managed physicians and helped oversee the development of oncology compounds, including, Brivanib, YERVOY, SPRYCEL, Nivolimab, and Elotuzumab, as well as biomarker and companion diagnostics.    
 
"Ian will help drive the advancement of our pipeline, work with our senior management team on strategic transactions, and help to prioritize and advance our assets to the clinic," said Henry Ji, Ph.D., president and chief executive officer of Sorrento.

blog comments powered by Disqus
  • Solid Dosage Manufacturing Trends

    Solid Dosage Manufacturing Trends

    Tim Wright, Editor||March 6, 2015
    Big Pharma continues to unload in-house manufacturing, partnering with contract service providers that can meet their cGMP needs.

  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 21, 2014
    Big Pharma continues to face the impact of competitive pressures, fluctuating currencies, the patent cliff, and pipeline surprises, all of which were reflected in financial results last year.

  • Newsmakers: Nancy Lurker

    Newsmakers: Nancy Lurker

    Gil Roth, Editor||March 7, 2014
    A CSO adapts for a new era in healthcare.